Generate Biomedicines Inc... (GENB)
Generate Biomedicines Inc. (GENB) Stock Price, Analysis & Data
| Bid | 10.88 |
| Market Cap | 1.93B |
| Revenue (ttm) | 26.48M |
| Net Income (ttm) | -268.67M |
| Beta | n/a |
| EPS (ttm) | -2.08 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.59 |
| P/B (ttm) | 4.23 |
| P/S (ttm) | 72.84 |
| Earnings Date | Nov 5, 2026 |
| Ask | 19.21 |
| Volume | 503,047 |
| Avg. Volume (20D) | 842,920 |
| Open | 15.19 |
| Previous Close | 15.09 |
| Day's Range | 14.90 - 15.48 |
| 52-Week Range | 11.00 - 18.18 |
| Analyst | Strong Buy |
| Price Target | 25 (66.33%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GENB
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an ...
Financial Performance
In 2025, Generate Biomedicines's revenue was 31.89M, an increase of 55.89% compared to the previous year's 20.46M. Earnings were -203.15M, an increase of 16.91%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for GENB stock is "Strong Buy". The 12-month stock price forecast is 25, which is upside of 66.33% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
2 weeks ago · The Wall Street Journal
Jersey Mike’s Is the Latest Stock Slide in Trading Debuts This YearJersey Mike’s Subs, with its 5.96% stock-price decline Thursday, is hardly alone in having a first-day share slide. This year, shares for hedge fund Pershing Square, nuclear fuel company Standard Nucl...
1 month ago · GuruFocus.com
Cathie Wood Dumps AMD, Doubles Down on Meta StockCathie Wood's Latest Trade: Big Meta Bet, Fresh AMD Sell-Off
